Stanley Laman Group Ltd. Buys 10,088 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 36.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,531 shares of the company's stock after purchasing an additional 10,088 shares during the quarter. Stanley Laman Group Ltd.'s holdings in Neurocrine Biosciences were worth $4,324,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in NBIX. Commonwealth Equity Services LLC boosted its position in Neurocrine Biosciences by 0.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company's stock valued at $1,923,000 after purchasing an additional 84 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of Neurocrine Biosciences by 0.8% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock worth $1,574,000 after acquiring an additional 90 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Neurocrine Biosciences by 14.7% in the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company's stock worth $99,000 after acquiring an additional 92 shares during the period. Total Clarity Wealth Management Inc. lifted its position in Neurocrine Biosciences by 4.3% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after purchasing an additional 100 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in Neurocrine Biosciences by 1.1% during the 1st quarter. Park Avenue Securities LLC now owns 9,570 shares of the company's stock valued at $1,320,000 after purchasing an additional 101 shares during the period. Institutional investors own 92.59% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup lifted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a report on Friday, August 2nd. Morgan Stanley lifted their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an "overweight" rating in a research note on Friday, July 12th. Oppenheimer increased their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Guggenheim upped their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Finally, Raymond James reissued an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $163.91.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded down $1.70 during midday trading on Wednesday, reaching $115.08. The stock had a trading volume of 581,975 shares, compared to its average volume of 848,916. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98. The firm has a market cap of $11.58 billion, a price-to-earnings ratio of 31.70 and a beta of 0.36. The firm's fifty day simple moving average is $124.09 and its two-hundred day simple moving average is $134.34.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to analysts' expectations of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business's quarterly revenue was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.95 EPS. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company's stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Matt Abernethy sold 14,100 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the transaction, the chief financial officer now owns 31,528 shares of the company's stock, valued at approximately $4,741,180.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company's stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,968 shares of company stock valued at $8,999,632 over the last three months. 4.30% of the stock is owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.